Tradestie Institutional Equity Comparison Engine
AYTU vs AIM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AYTU Overall Edge
AYTU Captures Institutional Edge (2โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AYTU BioPharma, Inc. Common Stock (AYTU) driven by superior Growth & Margin, Momentum & Technical while AIM counters with relative strength in Valuation. Fundamentally, AYTU trades at 9.2x Forward P/E with -14.4% operating margin (+6.4% YoY revenue) versus AIM at 2.0x Forward P/E and -11724.2% operating margin (+4.0% YoY). In options structure, AYTU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AIM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
AIM
AYTU 9.2x vs AIM 2.0x Fwd P/E
Growth & Margin Winner
AYTU
Op Margin -14.4% vs -11724.2% ยท YoY +6.4% vs +4.0%
Momentum & Technical Winner
AYTU
1Y -12.1% vs -90.9% ยท 52W Pos 5% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
AYTU
NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap
$19.6M
1M Return
-11.27%
1Y Return
-12.14%
Forward P/E
9.2x
Unified AI Score
48.9 / 100
HOLD
Tech 49.0
Fund 53.0
Flow 50.0
Mom 64.0
AIM
NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.13
-7.1% 1D
Market Cap
$5.9M
1M Return
-20.64%
1Y Return
-90.89%
Forward P/E
2.0x
Unified AI Score
52.8 / 100
HOLD
Tech 54.0
Fund 57.0
Flow 50.0
Mom 68.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AYTU -12.14%
AIM -90.89%
Spread: +78.75 pp (AYTU Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AYTU Revenue | AIM Revenue | AYTU Op. Margin | AIM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -230.1% | -8887.9% | AYTU |
| FY2020 | $30M | $0M | -76.5% | -9295.7% | AYTU |
| FY2021 | $70M | $0M | -89.7% | -13954.1% | AYTU |
| FY2022 | $100M | $0M | -113.7% | -14129.8% | AYTU |
| FY2023 | $110M | $0M | -15.9% | -15800.0% | AYTU |
| FY2024 | $70M | $0M | -2.4% | -11630.6% | AYTU |
| FY2025 | $70M | $0M | -11.8% | -13254.5% | AYTU |
| FY2026 | $60M | N/A | -14.4% | N/A | AYTU |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AYTU | AIM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.6M | $5.9M | Larger Scale | AYTU |
| Trailing P/E Ratio Valuation | 9.2x | 2.0x | Lower Multiple | AIM |
| Forward P/E Ratio Valuation | 9.2x | 2.0x | Lower Multiple | AIM |
| Revenue Growth (YoY) Growth | +6.4% | +4.0% | Higher Growth | AYTU |
| Operating Margin (TTM) Profitability | -14.4% | -11724.2% | Higher Margin | AYTU |
| Net Profit Margin Profitability | -24.8% | 0.0% | Higher Margin | AIM |
| Return on Equity (ROE) Capital Efficiency | -52.5% | -2382.3% | Higher ROE | AYTU |
| 52-Week Range Position Momentum | 5% ($2โ$3) | 1% ($0โ$2) | Stronger Trend | AYTU |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 35% Vol | 0.32ฮฒ ยท 69% Vol | Lower Realized Risk | AYTU |
| Unified Institutional Score Composite Signal | 48.9 / 100 (HOLD) | 52.8 / 100 (HOLD) | Higher Composite | AIM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AYTU vs AIM Buy Guide
AYTU
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
AIM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AYTU nor AIM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.